ENDRA Life Sciences Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirements [Yahoo! Finance]
ENDRA Life Sciences Inc. (NDRA)
US:NASDAQ Investor Relations:
investors.endrainc.com/prviewer/release_only/id/2807436
Company Research
Source: Yahoo! Finance
announced that on August 27, 2024, the Company was notified by The Nasdaq Stock Market LLC ("Nasdaq") that the Nasdaq Hearings Panel (the "Panel") has granted the Company's request for an extension through November 20, 2024, to evidence compliance with the $1.00 bid price requirement for continued listing on The Nasdaq Capital Market. To regain compliance with the bid price requirement, the Company must evidence a closing bid price of at least $1.00 per share for a minimum of 10 consecutive trading sessions on or before November 20, 2024. The Company is considering all available options to timely evidence compliance with the terms of the Panel's decision. This notification from Nasdaq has no immediate effect on the listing or trading of the Company's common stock, which will continue to trade on the Nasdaq Capital Market under the symbol "NDRA." The Company is also announcing that as of today, 91% of the Series B Warrants that were issued in connection with the June 2024 public
Show less
Read more
Impact Snapshot
Event Time:
NDRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NDRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NDRA alerts
High impacting ENDRA Life Sciences Inc. news events
Weekly update
A roundup of the hottest topics
NDRA
News
- ENDRA Life Sciences Reports Third Quarter 2024 Financial Results and Provides a Business Update [Yahoo! Finance]Yahoo! Finance
- ENDRA Life Sciences Reports Third Quarter 2024 Financial Results and Provides a Business UpdateBusiness Wire
- Study Highlighting ENDRA Life Sciences’ TAEUS Technology in Patients with High BMI to be Presented at AASLD’s The Liver Meeting® 2024Business Wire
- ENDRA Life Sciences Further Strengthens TAEUS® Platform Intellectual Property with Issuance of 17th European PatentBusiness Wire
- ENDRA Life Sciences Activates TAEUS System to Initiate Clinical Study at LMU University Hospital in GermanyBusiness Wire
NDRA
Sec Filings
- 11/21/24 - Form 10-Q/A
- 11/19/24 - Form 10-Q
- 11/15/24 - Form 8-K
- NDRA's page on the SEC website